Literature DB >> 9790463

Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma.

N H Chow1, K S Cheng, P W Lin, S H Chan, W C Su, Y N Sun, X Z Lin.   

Abstract

This study was performed to examine the immunohistochemical expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and a total of 31 cases of hepatocellular carcinoma (HCC). Reactivity for both types of angiogenic factor did not exist in any cellular component of normal liver. For HCC, variable amounts of fibroblast growth factor-1 were detected in 6 of 31 cases (19.4%). There was no apparent relationship between the expression pattern and clinicopathologic factors (P > 0.1, respectively), except a positive correlation with histologic grading (P = 0.04). No tumor showed reactivity for fibroblast growth factor-2 in their cancer cells. However, both types of peptide could be demonstrated in the pericellular stroma of HCC. With a mean follow-up at 60 months, fibroblast growth factor-1 expression did not correlate with patients' outcome (P > 0.1). Our study suggested that fibroblast growth factor-1 appears to play a certain role in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790463     DOI: 10.1023/a:1026670723302

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo.

Authors:  E G Nabel; Z Y Yang; G Plautz; R Forough; X Zhan; C C Haudenschild; T Maciag; G J Nabel
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

2.  Expression of epidermal growth factor and fibroblast growth factor in human hepatocellular carcinoma: an immunohistochemical study.

Authors:  Y Motoo; N Sawabu; Y Nakanuma
Journal:  Liver       Date:  1991-10

3.  Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study.

Authors:  N H Chow; P I Hsu; X Z Lin; H B Yang; S H Chan; K S Cheng; S M Huang; I J Su
Journal:  Hum Pathol       Date:  1997-06       Impact factor: 3.466

4.  Heparan sulfate proteoglycan expression in normal human liver.

Authors:  T Roskams; H Moshage; R De Vos; D Guido; P Yap; V Desmet
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

5.  Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract.

Authors:  H Ohtani; S Nakamura; Y Watanabe; T Mizoi; T Saku; H Nagura
Journal:  Lab Invest       Date:  1993-05       Impact factor: 5.662

6.  Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair.

Authors:  G F Pierce; J E Tarpley; D Yanagihara; T A Mustoe; G M Fox; A Thomason
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

7.  Sinusoidal capillarization of human hepatocellular carcinoma: possible promotion by fibroblast growth factor.

Authors:  Y Motoo; N Sawabu; Y Yamaguchi; T Terada; Y Nakanuma
Journal:  Oncology       Date:  1993 Jul-Aug       Impact factor: 2.935

8.  Studies on the biological characterization and mitogenic interactions between hepatic stimulator substance and acidic fibroblast growth factor.

Authors:  S Gupta; M Kan; R P Vemuru; D R Labrecque; W L McKeehan
Journal:  Cancer Lett       Date:  1994-04-01       Impact factor: 8.679

9.  Expression of fibroblast growth factors in thyroid cancer.

Authors:  M C Eggo; J M Hopkins; J A Franklyn; G D Johnson; D S Sanders; M C Sheppard
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

10.  Immunocytochemical localization of fibroblast growth factor-1 (FGF-1) and FGF-2 in oral squamous cell carcinoma (SCC).

Authors:  Y Myoken; Y Myoken; T Okamoto; J D Sato; K Takada
Journal:  J Oral Pathol Med       Date:  1994-11       Impact factor: 4.253

View more
  8 in total

1.  Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism.

Authors:  Chad M Novince; Megan N Michalski; Amy J Koh; Benjamin P Sinder; Payam Entezami; Matthew R Eber; Glenda J Pettway; Thomas J Rosol; Thomas J Wronski; Ken M Kozloff; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

2.  Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study.

Authors:  Zhi Li Wang; Ping Liang; Bao Wei Dong; Xiao Ling Yu; De Jiang Yu
Journal:  J Gastrointest Surg       Date:  2007-10-18       Impact factor: 3.452

3.  Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.

Authors:  W C Su; S C Shiesh; H S Liu; C Y Chen; N H Chow; X Z Lin
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

4.  Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.

Authors:  Jen-Chieh Lee; Sheng-Yao Su; Chun A Changou; Rong-Sen Yang; Keh-Sung Tsai; Michael T Collins; Eric S Orwoll; Chung-Yen Lin; Shu-Hwa Chen; Shyang-Rong Shih; Cheng-Han Lee; Yoshinao Oda; Steven D Billings; Chien-Feng Li; G Petur Nielsen; Eiichi Konishi; Fredrik Petersson; Thomas O Carpenter; Kesavan Sittampalam; Hsuan-Ying Huang; Andrew L Folpe
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

5.  The FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis.

Authors:  Hengliang Shi; Chunling Fu; Wei Wang; Yu Li; Shuang Du; Rangjuan Cao; Jingying Chen; Dong Sun; Zhongyu Zhang; Xingzhi Wang; Xiaojuan Zhu
Journal:  J Cell Mol Med       Date:  2014-08-15       Impact factor: 5.310

6.  Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells.

Authors:  Xiao-Xiao He; Shuang Du; Shi-Qian Gao; Jing-Ying Chen; Ran-Juan Cao; Zhen-Kai Xing; Alia Rizvi Syeda Kazim; Hua-Li Yu; Qing-Chuan Zheng; Xiao-Juan Zhu
Journal:  J Cell Mol Med       Date:  2018-03-24       Impact factor: 5.310

7.  Signs of carcinogenicity induced by parathion, malathion, and estrogen in human breast epithelial cells (Review).

Authors:  Gloria M Calaf; Tammy C Bleak; Debasish Roy
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

8.  Antitumoral effects of γCdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell.

Authors:  Sarah N C Gimenes; Daiana S Lopes; Patrícia T Alves; Fernanda V P V Azevedo; Lara Vecchi; Luiz R Goulart; Thais C S Rodrigues; André L Q Santos; Vera L de C Brites; Thaise L Teixeira; Cláudio V da Silva; Matheus H Dias; Samuel C Teixeira; Renata S Rodrigues; Kelly A G Yoneyama; Ricardo A Oliveira; Veridiana de M Rodrigues
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.